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 Extranodal natural killer (NK)/T-cell lymphoma, nasal type (ENKL), is a rare entity 
characterized by extranodal involvement and association with Epstein–Barr virus (EBV). 
Treatment with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone)-like therapies 
alone generally does not provide durable remissions(Tse & Kwong, 2013). While chemo-
radiation (for limited stage disease) or L-asparaginase-containing regimens (for advanced stage 
disease) have improved outcomes, ~40-50% of patients experience progression/relapse(Tse & 
Kwong, 2016). The median survival of advanced stage or relapsed ENKL is poor at ~6-12 
months(Suzuki, 2010, Au et al, 2009). The role of allogeneic haematopoietic cell transplantation 
(allo-HCT) has been explored in a few small retrospective studies, which almost exclusively 
were comprised of Asian patients (Table 1S). Studies evaluating allo-HCT for ENKL in a North 
American/European cohort are not available. Using the observational database of the Center for 
International Blood and Marrow Transplant Research (CIBMTR), we report here the largest 
analysis and the only study to include Caucasian patients. 
Adult (≥18 years) ENKL patients undergoing allo-HCT between 2000 and 2014 were 
included. Central biopsy report review by expert haematopathologist was required for inclusion 
(details of methods, study definitions and statistical analysis are provided in Supplemental 
Appendix). The baseline patient-, disease- and transplantation-characteristics of 82 ENKL 
patients undergoing allo-HCT are described in Table I. The median age at the time of allo-HCT 
was 44years (range: 20-70); 66% were male and 78% had Karnofsky performance score of 
≥80%. Recipients were predominantly Caucasian (66%), 19% were of Asian ethnicity. The 
disease status at the time of HCT was complete remission (CR), partial remission (PR) and 
chemorefractory disease in 45% 30% and 12%, respectively. The majority of patients received 
peripheral blood grafts (89%) from matched related donors (61%). Reduced-intensity (RIC) or 
myeloablative conditioning (MAC) was used in 59% and 38% of cases, respectively.   
 Table 2S describes post-transplantation outcomes. With a median follow-up of 36 
months (range: 1-121), the cumulative incidence of non-relapse mortality (NRM) and relapse at 
3 years were 30% (95%confidence interval [CI]: 20-40) and 42% (95%CI: 32-53), respectively 
(Figure 1A-B). The corresponding 3-year progression-free (PFS) and overall survival (OS) were 
28% (95%CI:19-39) and 34% (95%CI:24-45), respectively (Figure 1C-D). No disease relapse 
was noted beyond the 2-year mark. At last follow-up 52 patients had died, with lymphoma 
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univariate analysis to identify factors predicting outcomes are described in Table 3S. We also 
built a univariate Cox proportional hazards model for each covariate (Table 4S).  Recipient race 
(Caucasian vs. Asian) did not significantly impact PFS (Hazard ratio [HR]=0.92, 95%CI: 0.47-
1.80, p=0.81) or OS (HR=1.17, 95%CI: 0.59-2.32, p=0.65). NK-prognostic index (NK-PI) 
(low/low intermediate-risk vs high intermediate/high-risk NK-PI) was not significantly associated 
with the risk of disease relapse (HR=0.81, 95%CI: 0.28-2.35, p=0.70), PFS (HR=0.89, 95%CI: 
0.37-2.12, p=0.80) or OS (HR=1.11, 95%CI: 0.44-2.80, p=0.83).  Among patients receiving late 
(after >1 line of prior therapy) vs. upfront allo-HCT (after first-line therapy), the risk of relapse 
(HR=0.86, 95%CI: 0.42-1.77, p=0.69), PFS (HR=1.10, 95%CI: 0.60-1.98, p=0.77) and OS 
(HR=1.20, 95%CI: 0.61-2.28, p=0.58) were not significantly different. Remission status at the 
time of allo-HCT (CR vs. PR vs. chemoresistant disease) did not impact the relapse risk 
(p=0.93), PFS (p=0.59) or OS (p=0.51).  There was no statistically significant difference 
between the outcomes of patients receiving RIC vs. MAC regimens in terms of relapse 
(HR=0.56, 95%CI: 0.26-1.21, p=0.14), NRM (HR=1.72, 95%CI: 0.75-3.92, p=0.20), PFS 
(HR=0.92, 95%CI: 0.54-1.58, p=0.77) and OS (HR=0.95, 95%CI: 0.54-1.68, p=0.85).  
  Literature evaluating the role of allo-HCT in ENKL is limited to small retrospective 
studies, exclusively in Asian populations( Table 1S) . The largest previously reported study 
included 22 patients with ENKL, noting a 2-year PFS and OS of 34% and 40%, 
respectively(Murashige et al, 2005). In this study, no disease relapse was reported beyond 10 
months, hinting at durable remissions with allo-HCT. In our analysis, allo-HCT in ENKL was 
associated with durable remission and survival in approximately one-third of the patients, with a 
3-year PFS and OS of 28% and 34%, respectively and, notably, no relapses were reported 
beyond 2 years post-transplantation, suggesting potent graft-versus-lymphoma effects. 
However, disease relapse remained the main reason for treatment failure and death.  This 
observation provides the unique opportunity for implementing better surveillance modalities in 
the first two years after transplantation or investigating novel maintenance strategies to mitigate 
risk of relapse(Kim et al, 2015, Iqbal et al, 2011, Koo et al, 2012, Tse & Kwong, 2013, Hari et al, 
2016).  
Post-transplant relapse risk, NRM and survival were not affected by patient race, 
remission status, NK-PI, prior L-asparaginase use, timing of HCT (late vs. upfront) or 
conditioning intensity. The current study is the only report to evaluate allo-HCT for ENKL in a 
predominantly Caucasian patient cohort. The similar 3-year OS, of 35% in Caucasian and 33% 
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cohorts. In our analysis, the 3-year PFS and OS by pre-HCT remission status were similar, 
suggesting that even a subset of patients with chemorefractory disease can benefit from allo-
HCT. The risk of disease relapse was numerically lower with MAC regimens compared to RIC 
(50% vs. 30%, p=0.07), albeit not statistically significant and was offset by higher NRM 
associated with MAC regimens (40% vs. 23%, p=0.12) resulting in no difference in PFS and OS 
by conditioning intensity. Murashige et al (2005), previously reported a 2-year NRM of 30% and 
20% with MAC and RIC regimens, comparable to our findings .  
Being a retrospective study utilizing registry data is an inherent limitation of this analysis. 
The sample size limits the power to detect small differences in outcomes in our population. 
Notwithstanding these limitations, this CIBMTR study evaluating the role of allo-HCT in ENKL is 
the largest study to date and included patients only after a careful central review of biopsy 
reports. In conclusion, our data suggests that allo-HCT is a viable curative option in a subset of 
ENKL and should be considered in advanced or relapsed/refractory disease irrespective of 
patient race. Relapse remains a major cause of treatment-failure, highlighting the need for 
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Table I.  Baseline characteristics of patients with extranodal NK/T-cell Lymphoma, nasal 
type 
 
Variable N=82 (%) 
Median age at HCT (range), years 44 (20-70) 
Male sex 54 (66) 
Karnofsky performance score before HCT  
 80-100% 64 (78) 
 < 80% 12 (15) 
 Unknown 6 (7) 
HCT-CI  
 0 35 (43) 
 1-2 16 (20) 
 ≥ 3  13 (16) 
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Variable N=82 (%) 
Race  
 Caucasian 54 (66) 
 Asian 16 (19) 
            Others1 or Unknown 12 (15) 
History of prior autologous HCT 11 (13) 
Median interval from diagnosis to HCT, months (range) 11 (3-137) 
            <1 year 47 (57) 
            ≥1 year 33 (40) 
Disease stage at diagnosis  
            Stage I/II 35 (43) 
            Stage III/IV 22 (27) 
            Unknown  25 (30) 
NK/T-cell Lymphoma Prognostic Index2  
            Low or low-intermediate 7 (8) 
            High or high-intermediate 26 (32) 
            Unknown 49 (60) 
First line of therapy  
             Chemotherapy alone (n=41) 
                    CHOP- or HyperCVAD-like 
                    DeVIC or VIPD 
                    SMILE 
                    AspaMetDex 
                    Gemcitabine-based 
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Variable N=82 (%) 
              Chemotherapy + radiation (n=27) 
                    CHOP- or HyperCVAD-like + Radiation 
                    De-VIC or VIPD + Radiation 
                    SMILE + Radiation 
                    AspaMetDex + Radiation 
                    Other + Radiation 
              Radiation alone (n=5) 









Response to first line of therapy  
              Complete remission 25 (30) 
              Partial remission 23 (28) 
              Refractory disease 18 (22) 
              Unknown 16 (20) 
Median (range) lines of therapy before HCT 2 (1-7) 
Received L/peg-asparaginase containing therapy (any 
time before HCT) 
31 (38)  
Timing of transplantation  
              Upfront (after first line therapy) 25 (30) 
              Late (>1 line of therapy prior to HCT) 49 (60) 
              Unknown           8 (10) 
Remission status prior to HCT  
 Complete remission 37 (45) 
            Partial remission  25 (30) 
 Chemorefractory  10 (12) 
 Untreated /unknown 10 (12) 
Donor type  
 Matched related donor 50 (61) 
 Unrelated donor 23 (28) 
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Variable N=82 (%) 
 Haploidentical related donor 3 (4) 
            Missing  1 (1) 
Conditioning regimen intensity  
 Reduced-intensity conditioning  48 (59) 
 Myeloablative conditioning  31 (38) 
            Missing     3 (4) 
Graft Source  
 Bone marrow 4 (5) 
 Peripheral blood 73(89) 
            Cord blood 5 (6) 
GVHD prophylaxis  
 Calcineurin inhibitor + mycophenolate mofetil   23 (28) 
 Calcineurin inhibitor + methotrexate ± others3 35 (43) 
 Calcineurin inhibitor ± others4 16 (20) 
 Others5 6 (6) 
            Missing 2 (2) 
Donor or recipient CMV positive 57 (69) 
Number of centers 43 
Median follow-up of survivors (range), months 3 (1-121) 
Abbreviations: AspaMetDex = pegaspargase, methotrexate, dexamethasone; CHOP = 
cyclophosphamide, doxorubicin, vincristine, prednisone; CMV = cytomegalovirus; DeVIC = 
dexamethasone, etoposide, ifosfamide and carboplatin; GVHD = graft-versus-host disease; 
HCT = haematopoietic cell transplantation; HCT-CI = haematopoietic cell transplantation-
comorbidity index; Hyper-CVAD = hyperfractionated cyclophosphamide, doxorubicin, 
vincristine, dexamethasone; SMILE = steroid, methotrexate, ifosfamide, L-asparaginase, 
etoposide; VIPD = etoposide, ifosfamide, cisplatin, dexamethasone.  
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2NK/T-cell Lymphoma Prognostic score - 1 point for each of the following: serum lactate 
dehydrogenase > normal, B symptoms at diagnosis, lymph node involvement at diagnosis, 
Ann Arbor stage IV at diagnosis. Low: 0, Low-intermediate: 1, High-Intermediate: 2, High: 3-
4 
3Calcineurin inhibitor+methotrexate alone (n=31) or with sirolimus (n=4) 
4Calceneurin inhibitors alone (n=8), or with steroid (n=2), or with sirolimus (n=6) 
5
 
Mycophenolate/sirolimus (n=1), sirolimus (n=1), post-transplant cyclophosphamide-based 
(n=3), CD34 selection (n=1) 
 
Figure Legends:  
Figure 1.  
Cumulative incidence of non-relapse mortality (1A) and lymphoma relapse (1B) and 
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